Drug Profile
Fluvastatin
Alternative Names: Canef; Cranoc; Digaril; Fractal; Hovalin; Lescol; Lescol XL; Lipaxan; Lochol; Lymetel; Primesin; SRI 62320; Vastin; XU 62320Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer AbbVie; Almirall S.A.; AstraZeneca; Bayer; Berenguer-Infale; Italfarmaco; Mitsubishi Tanabe Pharma Corporation; Novartis; Pierre Fabre; Reliant Pharmaceuticals; Sanofi; sanofi-aventis; Solvay
- Class Antihyperlipidaemics; Indoles; Monounsaturated fatty acids
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia; Hypertriglyceridaemia
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 18 Sep 2015 First Generic equivalent available in USA for Hyperlipidaemia
- 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
- 13 Apr 2012 Generic equivalent approved in USA for familial & non-familial hypercholesterolaemia, mixed dyslipidaemia & secondary prevention of cardiovascular disease